Merck & Co. (NYSE: MRK) presented additional data from Phase 3 trials of its investigational HIV treatment doravirine/islatravir (DOR/ISL) at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE